KCA
Search
- Page Path
- HOME > Search
Original Article
-
Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models
- Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun-Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung-Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae-Hoon Kim, Young Tae Kim, Eun Ji Nam
- Cancer Res Treat. 2018;50(3):956-963. Published online October 17, 2017
- DOI: https://doi.org/10.4143/crt.2017.181
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Although the use of xenograft models is increasing, few studies have compared the clinical features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumorigenicity of engrafted specimens. The purpose of this study was to evaluate whether tumorigenicity was associated with the clinical features and outcomes of EOC patients.
Materials and Methods
Eighty-eight EOC patients who underwent primary or interval debulking surgery from June 2014 to December 2015 were included. Fresh tumor specimens were implanted subcutaneously on each flank of immunodeficient mice. Patient characteristics, progression-free survival (PFS), and germline mutation spectra were compared according to tumorigenicity.
Results
Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was associated with lymphovascular invasion and there was a propensity to engraft successfully with high-grade tumors. Tumors from patientswho underwent non-optimal (residual disease ≥ 1 cm) primary orinterval debulking surgery had a significantly greater propensity to achieve tumorigenicity than those who received optimal surgery. In addition, patients whose tumors became engrafted seemed to have a shorter PFS and more frequent germline mutations than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for predicting PFS with advanced International Federation of Gynecology and Obstetrics stage and high-grade cancers.
Conclusions
Tumorigenicity in a xenograft model was a strong prognostic factor and was associated with more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical tool to predict prognosis and could be applied to further pharmacologic and genomic studies on personalized treatments. -
Citations
Citations to this article as recorded by
- TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer
Christos Vaklavas, Cindy B. Matsen, Zhengtao Chu, Kenneth M. Boucher, Sandra D. Scherer, Satya Pathi, Anna Beck, Kirstyn E. Brownson, Saundra S. Buys, Namita Chittoria, Elyse D'Astous, H. Evin Gulbahce, N. Lynn Henry, Stephen Kimani, Jane Porretta, Regina
JCO Precision Oncology.2024;[Epub] CrossRef - Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai
Cancer Cell International.2023;[Epub] CrossRef - Cancer “Avatars”: Patient-Derived Xenograft Growth Correlation with Postoperative Recurrence and Survival in Pancreaticobiliary Cancer
Isaac T Lynch, Amro M Abdelrahman, Roberto Alva-Ruiz, Alessandro Fogliati, Rondell P Graham, Rory Smoot, Mark J Truty
Journal of the American College of Surgeons.2023; 237(3): 483. CrossRef - Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models
Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho, Jae-Hoon Kim
Cancers.2022; 14(3): 829. CrossRef - Experimental models for ovarian cancer research
Sum In Tsang, Ayon A. Hassan, Sally K.Y. To, Alice S.T. Wong
Experimental Cell Research.2022; 416(1): 113150. CrossRef - Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
Alessandra Ciucci, Marianna Buttarelli, Anna Fagotti, Giovanni Scambia, Daniela Gallo
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef - Harnessing preclinical models for the interrogation of ovarian cancer
Tianyu Qin, Junpeng Fan, Funian Lu, Li Zhang, Chen Liu, Qiyue Xiong, Yang Zhao, Gang Chen, Chaoyang Sun
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef - Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas
Helena Castillo‐Ecija, Guillem Pascual‐Pasto, Sara Perez‐Jaume, Claudia Resa‐Pares, Monica Vila‐Ubach, Carles Monterrubio, Ana Jimenez‐Cabaco, Merce Baulenas‐Farres, Oscar Muñoz‐Aznar, Noelia Salvador, Maria Cuadrado‐Vilanova, Nagore G Olaciregui, Leire B
The Journal of Pathology: Clinical Research.2021; 7(4): 338. CrossRef - Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review
Tomohito Tanaka, Ruri Nishie, Shoko Ueda, Shunsuke Miyamoto, Sousuke Hashida, Hiromi Konishi, Shinichi Terada, Yuhei Kogata, Hiroshi Sasaki, Satoshi Tsunetoh, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
International Journal of Molecular Sciences.2021; 22(17): 9369. CrossRef - Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine
Jennifer L. Leiting, Stephen J. Murphy, John R. Bergquist, Matthew C. Hernandez, Tommy Ivanics, Amro M. Abdelrahman, Lin Yang, Isaac Lynch, James B. Smadbeck, Sean P. Cleary, David M. Nagorney, Michael S. Torbenson, Rondell P. Graham, Lewis R. Roberts, Gr
JHEP Reports.2020; 2(2): 100068. CrossRef - Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer
Qi Chen, Tao Wei, Jianxin Wang, Qi Zhang, Jin Li, Jingying Zhang, Lei Ni, Yi Wang, Xueli Bai, Tingbo Liang
Pancreatology.2020; 20(3): 485. CrossRef - A Biobank of Colorectal Cancer Patient-Derived Xenografts
Suad M. Abdirahman, Michael Christie, Adele Preaudet, Marie C. U. Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M. Sieber, Tracy L. Putoczki
Cancers.2020; 12(9): 2340. CrossRef - High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Michael-Antony Lisio, Lili Fu, Alicia Goyeneche, Zu-hua Gao, Carlos Telleria
International Journal of Molecular Sciences.2019; 20(4): 952. CrossRef - Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors
Yoshiaki Maru, Naotake Tanaka, Makiko Itami, Yoshitaka Hippo
Gynecologic Oncology.2019; 154(1): 189. CrossRef - Current Status of Patient-Derived Ovarian Cancer Models
Yoshiaki Maru, Yoshitaka Hippo
Cells.2019; 8(5): 505. CrossRef - Establishment of patient‐derived xenograft model in ovarian cancer and its influence factors analysis
Jianfa Wu, Yunxi Zheng, Qi Tian, Ming Yao, Xiaofang Yi
Journal of Obstetrics and Gynaecology Research.2019; 45(10): 2062. CrossRef - Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi
Medicines.2018; 5(1): 16. CrossRef
- TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer
- 8,760 View
- 238 Download
- 18 Web of Science
- 17 Crossref
First
Prev
